优化纯化灭活寨卡疫苗在小鼠中的免疫原性与保护效果
研究比较了Sanofi Pasteur优化后的纯化灭活寨卡疫苗(ZPIV-SP)与第一代ZPIV在BALB/c和A129小鼠中的免疫原性与保护效果。ZPIV-SP诱导了强效血清中和抗体应答,在免疫健全BALB/c小鼠中提供对同源寨卡病毒株攻击的完全保护,并在 interferon 受体缺陷A129小鼠中显示改进的免疫原性和效力。NS1 IgG应答分析提示优化纯化工艺有效去除了病毒NS1蛋白。
要点
- ZPIV-SP在BALB/c小鼠中诱导强效血清中和抗体并完全抵御同源寨卡病毒攻击。
- ZPIV-SP较第一代疫苗免疫原性改善,在A129小鼠中效力更优。
- 优化纯化工艺有效去除NS1,支持推进大动物模型和后期临床研究。
核心结论
- 优化后的ZPIV-SP在免疫健全BALB/c小鼠中提供对同源寨卡病毒攻击的完全保护。
- ZPIV-SP较第一代疫苗免疫原性改善,在干扰素受体缺陷A129小鼠中效力更优。
- 优化纯化工艺有效去除NS1,提示ZPIV-SP适合进一步大动物模型和后期临床评价。
研究设计与样本
- 临床前小鼠免疫原性与攻毒保护研究,使用免疫健全BALB/c小鼠和干扰素受体缺陷A129小鼠。
主要发现
- ZPIV-SP诱导强效血清中和抗体应答,在BALB/c小鼠中提供对同源寨卡病毒株攻击的完全保护。
- ZPIV-SP较第一代疫苗免疫原性改善,在A129小鼠中效力更优。
- 针对NS1的IgG应答分析提示优化纯化过程有效去除病毒NS1。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After decades of inconsequential infections, and sporadic outbreaks in the Asia-Pacific region between 2007 and 2013, Zika virus caused a widespread epidemic in South America in 2015 that was complicated by severe congenital infections. After the WHO declared a Public Health Emergency of International Concern in February 2016, vaccine development efforts based on different platforms were initiated. Several candidates have since been evaluated in clinical phase I studies. Of these, a Zika purified inactivated vaccine (ZPIV), adjuvanted with aluminum hydroxide, developed by the Walter Reed Army Institute of Research (WRAIR), yielded high seroconversion rates. Sanofi Pasteur further optimized the vaccine in terms of production scale, purification conditions and regulatory compliance, using its experience in flavivirus vaccine development. Here we report that the resulting optimized vaccine (ZPIV-SP) elicited robust seroneutralizing antibody responses and provided complete protection from homologous Zika virus strain challenge in immunocompetent BALB/c mice. ZPIV-SP also showed improved immunogenicity compared with the first-generation vaccine, and improved efficacy in the more permissive interferon receptor-deficient A129 mice. Finally, analysis of the IgG response directed towards nonstructural protein 1 (NS1) suggests that viral NS1 was efficiently removed during the optimized purification process of ZPIV-SP. Together, these results suggest that the optimized vaccine is well suited for further evaluation in larger animal models and late-stage clinical studies.
引用
- Lecouturier V, Bernard MC, Berry C, et al. Immunogenicity and protection conferred by an optimized purified inactivated Zika vaccine in mice. Vaccine. 2019. PMID: 30967310. doi:10.1016/j.vaccine.2019.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。